Inhaled Reliever Therapies for Asthma

医学 福莫特罗 哮喘 随机对照试验 梅德林 相对风险 不利影响 数据提取 生活质量(医疗保健) 内科学 儿科 布地奈德 置信区间 护理部 政治学 法学
作者
Daniel Rayner,Dario Ferri,Gordon H. Guyatt,Paul M. O’Byrne,Romina Brignardello‐Petersen,Farid Foroutan,Bradley E. Chipps,Kaharu Sumino,Tamara T. Perry,Sharmilee M. Nyenhuis,John Oppenheimer,Elliot Israel,Flavia Hoyte,Katherine Rivera‐Spoljaric,Ellen M. McCabe,S. Rangel,Lindsay Shade,Valerie G. Press,Lisa Hall,Dia Sue-Wah-Sing,Angel Melendez,H. C. Orr,Tonya Winders,Donna D. Gardner,Kathryn M. Przywara,Matthew A. Rank,Leonard B. Bacharier,Giselle Mosnaim,Derek K. Chu
出处
期刊:JAMA [American Medical Association]
标识
DOI:10.1001/jama.2024.22700
摘要

Importance The optimal inhaled reliever therapy for asthma remains unclear. Objective To compare short-acting β agonists (SABA) alone with SABA combined with inhaled corticosteroids (ICS) and with the fast-onset, long-acting β agonist formoterol combined with ICS for asthma. Data Sources The MEDLINE, Embase, and CENTRAL databases were searched from January 1, 2020, to September 27, 2024, without language restrictions. Study Selection Pairs of reviewers independently selected randomized clinical trials evaluating (1) SABA alone, (2) ICS with formoterol, and (3) ICS with SABA (combined or separate inhalers). Data Extraction and Synthesis Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses synthesized outcomes. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to evaluate the certainty of evidence. Main Outcomes and Measures Asthma symptom control (5-item Asthma Control Questionnaire; range, 0-6, lower scores indicate better asthma control; minimum important difference [MID], 0.5 points), asthma-related quality of life (Asthma Quality of Life Questionnaire; range, 1-7, higher scores indicate better quality of life; MID, 0.5 points), risk of severe exacerbations, and risk of serious adverse events. Results A total of 27 randomized clinical trials (N = 50 496 adult and pediatric patients; mean age, 41.0 years; 20 288 male [40%]) were included. Compared with SABA alone, both ICS-containing relievers were associated with fewer severe exacerbations (ICS-formoterol risk ratio [RR], 0.65 [95% CI, 0.60-0.72]; risk difference [RD], −10.3% [95% CI, −11.8% to −8.3%]; ICS-SABA RR, 0.84 [95% CI, 0.73-0.95]; RD, −4.7% [95% CI, −8.0% to −1.5%]) with high certainty. Compared with SABA alone, both ICS-containing relievers were associated with improved asthma control (ICS-formoterol RR improvement [MID] in total score, 1.07 [95% CI, 1.04-1.10]; RD, 4.1% [95% CI, 2.3%-5.9%]; ICS-SABA RR, 1.09 [95% CI, 1.03-1.15]; RD, 5.4% [95% CI, 1.8%-8.5%]) with high certainty. In an indirect comparison with ICS-SABA, ICS-formoterol was associated with fewer severe exacerbations (RR, 0.78 [95% CI, 0.66-0.92]; RD, −5.5% [95% CI, −8.4% to −2.0%]) with moderate certainty. Compared with SABA alone, ICS-formoterol (RD, −0.6% [95% CI, −1.3% to 0%]) was not associated with increased risk of serious adverse events (high certainty) and ICS-SABA (RD, 0% [95% CI, −1.1% to 1.2%]) was not associated with increased risk of serious adverse events (moderate certainty). Conclusions and Relevance In this network meta-analysis of patients with asthma, ICS combined with formoterol and ICS combined with SABA were each associated with reduced asthma exacerbations and improved asthma control compared with SABA alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助1234采纳,获得10
1秒前
2秒前
double ting发布了新的文献求助20
3秒前
slz发布了新的文献求助10
3秒前
ding应助徐佳乐采纳,获得10
4秒前
4秒前
大模型应助自由路采纳,获得10
5秒前
lx33101128发布了新的文献求助10
5秒前
FreeRice发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
wanci应助嗯qq采纳,获得10
6秒前
7秒前
赘婿应助十月采纳,获得10
8秒前
curtisness应助Lycerdoctor采纳,获得10
8秒前
8秒前
ymr发布了新的文献求助30
8秒前
shinysparrow应助1351567822采纳,获得50
9秒前
10秒前
yy发布了新的文献求助10
10秒前
10秒前
Maestro_S发布了新的文献求助10
11秒前
清爽灰狼发布了新的文献求助10
12秒前
12秒前
Jasper应助hanlanx采纳,获得10
13秒前
废寝忘食发布了新的文献求助10
13秒前
13秒前
13秒前
14秒前
kkkkk完成签到,获得积分10
14秒前
smrsmr完成签到,获得积分10
14秒前
14秒前
1234发布了新的文献求助10
15秒前
嗯qq完成签到,获得积分10
15秒前
15秒前
16秒前
徐佳乐发布了新的文献求助10
16秒前
18秒前
18秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3148173
求助须知:如何正确求助?哪些是违规求助? 2799264
关于积分的说明 7834331
捐赠科研通 2456531
什么是DOI,文献DOI怎么找? 1307282
科研通“疑难数据库(出版商)”最低求助积分说明 628124
版权声明 601655